Oncology Venture provides further information on the terms for a proposed rights issue

Press release

Hoersholm, Denmark, September 4, 2019 – Oncology Venture A/S (Nasdaq First North Growth Market Stockholm: OV.ST) hereby provides clarification on the terms for the proposed rights issue, that was announced in a press release earlier today. As mentioned in the previous announcement, the company’s Board of Directors is proposing a rights issue where existing shareholders for each 7 shares held in the Company will receive the right to subscribe to 5 new shares. Each new share has a warrant attached. To avoid any misunderstanding, one new share (with a warrant attached) may be subscribed for against cash payment of SEK 2.

For further information, please contact:

Duncan Moore
Chairman of the Board, Oncology Venture A/S

E-mail: duncan@eastwestcap.com
Phone: +44 778 597 17 15

Claus Frisenberg Pedersen
Chief Commercial Officer
E-mail: cfp@oncologyventure.com
Phone: +45 61 61 66 41

About Oncology Venture A/S
Oncology Venture A/S (Nasdaq First North Growth Market Stockholm: OV.ST) develops drugs for personalized treatment of cancer guided by its proprietary drug response predictor technology, DRP®. The company has a mature portfolio of seven drug candidates, including compounds in pre-registration stage. Based on a pre-treatment biopsy, DRP® reveals the genetic fingerprint of an individual patient’s tumor and predicts the treatment response of a certain cancer drug or drug candidate. By including only patients with sensitive tumors in a clinical trial, it is possible to avoid background noise from non-sensitive patients in efficacy read-outs. Once a new drug is approved, DRP® can be used to identify just those patients who can benefit from treatment. Learn more at www.oncologyventure.com

Follow us on social media:
Facebook: https://www.facebook.com/oncologyventure/
LinkedIn: https://www.linkedin.com/company/oncology-venture/
Twitter: https://twitter.com/OncologyVenture

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OV’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OV’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OV undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, Email: ca@skmg.se. Tel: +46 11 32 30 732

Attachment

Sign up for press releases and receive relevant information about Oncology Venture A/S